SGMO - Sangamo reports updated data for gene therapy candidate ST-920
2025-02-06 13:56:32 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics: Left At The Altar (Rating Downgrade)
- Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
- Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
- Why did Pfizer's exit from gene therapy program hit Sangamo hard?
- Sangamo plunges 38% after Pfizer ends agreement on hemophilia A gene therapy